Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZL sequential CD19/CD22 CAR-T in R/R B-NHL
NCT05797948Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CD19/CD22 CAR-T in B-cell non-Hodgkin lymphoma, sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Overall response rate after GZL therapy, Complete response rate after CAR-T at 3 months and 1 more. Status: unknown.
02
Drugs
CD19/CD22 CAR-T
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05797948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797948.